Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer
International Journal of Cancer · 2025
DOI: 10.1002/ijc.70052 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Fenna de Vries und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, OLVG, Amsterdam, North-Holland, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Health Insurers, Stichting Treatmeds.
Abstract (Originalsprache)
Immune checkpoint inhibitors have improved survival rates in patients with advanced‐stage non‐small cell lung cancer; however, the majority obtain no long‐term benefits. We investigated pembrolizumab clearance as an early prognostic biomarker and evaluated its accuracy using a limited sampling strategy. Pembrolizumab clearance was calculated using non‐linear mixed effects modeling, and cut points were determined using maximally selected rank statistics. The prognostic value for survival was estimated using univariate Cox regression analysis. Sensitivity, specificity, and positive and negative predictive values were calculated to evaluate the performance in identifying response (defined as disease control at 6 months). The accuracy of a limited sampling strategy was evaluated using MPE and NRSME. Among 303 patients included, 65% experienced disease progression, and 60% died. Patients with pembrolizumab clearance above 0.232 L/day at the first dose were more likely to have disease progression (HR = 1.98, 95% CI [1.21, 3.26], p = .007) or poor survival (HR = 2.04, 95% CI [1.16, 3.59], p = .014). A diminished decrease in clearance (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, OLVG, Amsterdam, North-Holland, The Netherlands.
- Department of Pharmacy, Research Institute for Medical Innovation, Radboudumc, Nijmegen, Gelderland, the Netherlands.
- Department of Respiratory Medicine, Research Institute for Medical Innovation, Radboudumc, Nijmegen, Gelderland, the Netherlands.
- Department of Pulmonology, OLVG, Amsterdam, North-Holland, The Netherlands.
- Department of Pulmonology, University Medical Center Utrecht, Utrecht, the Netherlands.
ORCID-Profile: Fenna de Vries, Leila-Sophie Otten
Förderung
- Dutch Health Insurers
- Stichting Treatmeds
Zitieren
APA
de Vries, F., Otten, L. S., Piet, B., Franssen, E. J. F., Smit, A. A. J., van den Heuvel, M. M., Ter Heine, R., & DEDICATION‐1 Study Group (2025). Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70052
Vancouver
de Vries F, Otten LS, Piet B, Franssen EJF, Smit AAJ, van den Heuvel MM, et al. Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer. International Journal of Cancer. 2025. doi:10.1002/ijc.70052
BibTeX
@article{deVries2025,
author = {de Vries, Fenna and Otten, Leila-Sophie and Piet, Berber and Franssen, Eric J F and Smit, Arthur A J and van den Heuvel, Michel M and Ter Heine, Rob and DEDICATION‐1 Study Group, DEDICATION‐1 Study Group},
title = {Early pembrolizumab clearance as prognostic biomarker for non‐response in patients with advanced non‐small cell lung cancer},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.70052}
}
EUVIMED